Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INTERCEPT Plasma
- Development stage
- Discontinued
- Lead developer
- Cerus Corporation
- Administration
- Intravenous
01
Overview
INTERCEPT Plasma for Ebola virus disease is a pathogen-inactivated convalescent plasma therapy developed by Cerus Corporation. It is a medical device/biologic combination product that utilizes the INTERCEPT Blood System technology to treat convalescent plasma collected from Ebola survivors. The system employs a proprietary molecule (amotosalen) activated by ultraviolet (UVA) light to bind and cross-link DNA and RNA in the plasma, thereby inactivating potential pathogens (including Ebola virus, bacteria, and other transfusion-transmitted infections) while preserving therapeutic antibodies. The treated plasma is then transfused into patients with acute Ebola infections to provide passive immunity.
- Brand names
- INTERCEPT PlasmaINTERCEPT Blood System
- Other names
- pathogen-inactivated convalescent plasmaEBOV convalescent plasma
02
Targets
Nucleic acids in pathogens and contaminating leukocytes
Beyond the preview
Go deeper on INTERCEPT Plasma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INTERCEPT Plasma.